Design and methods of the Population Assessment of Tobacco and Health (PATH) Study

Andrew Hyland, Bridget K. Ambrose, Kevin P. Conway, Nicolette Borek, Elizabeth Lambert, Charles Carusi, Kristie Taylor, Scott Crosse, Geoffrey T. Fong, K. Michael Cummings, David Abrams, John P. Pierce, James Sargent, Karen Messer, Maansi Bansal-Travers, Ray Niaura, Donna Vallone, David Hammond, Nahla Hilmi, Jonathan Kwan & 21 others Andrea Piesse, Graham Kalton, Sharon Lohr, Nick Pharris-Ciurej, Victoria Castleman, Victoria R. Green, Greta Tessman, Annette Kaufman, Charles Lawrence, Dana M. Van Bemmel, Heather L. Kimmel, Ben Blount, Ling Yang, Barbara O’Brien, Cindy Tworek, Derek Alberding, Lynn C. Hull, Yu Ching Cheng, David Maklan, Cathy L. Backinger, Wilson M. Compton

Research output: Research - peer-reviewArticle

Abstract

Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study’s design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA’s regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation’s burden of tobacco-related death and disease.

LanguageEnglish (US)
Pages371-378
Number of pages8
JournalTobacco Control
Volume26
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

Tobacco
Health
Population
nicotine
health
Tobacco Products
Tobacco Use
United States Food and Drug Administration
Recurrence
National Institute on Drug Abuse (U.S.)
Tobacco Use Cessation
National Institutes of Health (U.S.)
Contracts
Longitudinal Studies
Cohort Studies
Biomarkers
Smoking
relapse
drug abuse
smoking

ASJC Scopus subject areas

  • Health(social science)
  • Public Health, Environmental and Occupational Health

Cite this

Hyland, A., Ambrose, B. K., Conway, K. P., Borek, N., Lambert, E., Carusi, C., ... Compton, W. M. (2017). Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tobacco Control, 26(4), 371-378. DOI: 10.1136/tobaccocontrol-2016-052934

Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. / Hyland, Andrew; Ambrose, Bridget K.; Conway, Kevin P.; Borek, Nicolette; Lambert, Elizabeth; Carusi, Charles; Taylor, Kristie; Crosse, Scott; Fong, Geoffrey T.; Michael Cummings, K.; Abrams, David; Pierce, John P.; Sargent, James; Messer, Karen; Bansal-Travers, Maansi; Niaura, Ray; Vallone, Donna; Hammond, David; Hilmi, Nahla; Kwan, Jonathan; Piesse, Andrea; Kalton, Graham; Lohr, Sharon; Pharris-Ciurej, Nick; Castleman, Victoria; Green, Victoria R.; Tessman, Greta; Kaufman, Annette; Lawrence, Charles; Van Bemmel, Dana M.; Kimmel, Heather L.; Blount, Ben; Yang, Ling; O’Brien, Barbara; Tworek, Cindy; Alberding, Derek; Hull, Lynn C.; Cheng, Yu Ching; Maklan, David; Backinger, Cathy L.; Compton, Wilson M.

In: Tobacco Control, Vol. 26, No. 4, 01.07.2017, p. 371-378.

Research output: Research - peer-reviewArticle

Hyland, A, Ambrose, BK, Conway, KP, Borek, N, Lambert, E, Carusi, C, Taylor, K, Crosse, S, Fong, GT, Michael Cummings, K, Abrams, D, Pierce, JP, Sargent, J, Messer, K, Bansal-Travers, M, Niaura, R, Vallone, D, Hammond, D, Hilmi, N, Kwan, J, Piesse, A, Kalton, G, Lohr, S, Pharris-Ciurej, N, Castleman, V, Green, VR, Tessman, G, Kaufman, A, Lawrence, C, Van Bemmel, DM, Kimmel, HL, Blount, B, Yang, L, O’Brien, B, Tworek, C, Alberding, D, Hull, LC, Cheng, YC, Maklan, D, Backinger, CL & Compton, WM 2017, 'Design and methods of the Population Assessment of Tobacco and Health (PATH) Study' Tobacco Control, vol 26, no. 4, pp. 371-378. DOI: 10.1136/tobaccocontrol-2016-052934
Hyland A, Ambrose BK, Conway KP, Borek N, Lambert E, Carusi C et al. Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tobacco Control. 2017 Jul 1;26(4):371-378. Available from, DOI: 10.1136/tobaccocontrol-2016-052934
Hyland, Andrew ; Ambrose, Bridget K. ; Conway, Kevin P. ; Borek, Nicolette ; Lambert, Elizabeth ; Carusi, Charles ; Taylor, Kristie ; Crosse, Scott ; Fong, Geoffrey T. ; Michael Cummings, K. ; Abrams, David ; Pierce, John P. ; Sargent, James ; Messer, Karen ; Bansal-Travers, Maansi ; Niaura, Ray ; Vallone, Donna ; Hammond, David ; Hilmi, Nahla ; Kwan, Jonathan ; Piesse, Andrea ; Kalton, Graham ; Lohr, Sharon ; Pharris-Ciurej, Nick ; Castleman, Victoria ; Green, Victoria R. ; Tessman, Greta ; Kaufman, Annette ; Lawrence, Charles ; Van Bemmel, Dana M. ; Kimmel, Heather L. ; Blount, Ben ; Yang, Ling ; O’Brien, Barbara ; Tworek, Cindy ; Alberding, Derek ; Hull, Lynn C. ; Cheng, Yu Ching ; Maklan, David ; Backinger, Cathy L. ; Compton, Wilson M./ Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. In: Tobacco Control. 2017 ; Vol. 26, No. 4. pp. 371-378
@article{ee5ca3926d674627ae07eb39d29a3282,
title = "Design and methods of the Population Assessment of Tobacco and Health (PATH) Study",
abstract = "Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study’s design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA’s regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation’s burden of tobacco-related death and disease.",
author = "Andrew Hyland and Ambrose, {Bridget K.} and Conway, {Kevin P.} and Nicolette Borek and Elizabeth Lambert and Charles Carusi and Kristie Taylor and Scott Crosse and Fong, {Geoffrey T.} and {Michael Cummings}, K. and David Abrams and Pierce, {John P.} and James Sargent and Karen Messer and Maansi Bansal-Travers and Ray Niaura and Donna Vallone and David Hammond and Nahla Hilmi and Jonathan Kwan and Andrea Piesse and Graham Kalton and Sharon Lohr and Nick Pharris-Ciurej and Victoria Castleman and Green, {Victoria R.} and Greta Tessman and Annette Kaufman and Charles Lawrence and {Van Bemmel}, {Dana M.} and Kimmel, {Heather L.} and Ben Blount and Ling Yang and Barbara O’Brien and Cindy Tworek and Derek Alberding and Hull, {Lynn C.} and Cheng, {Yu Ching} and David Maklan and Backinger, {Cathy L.} and Compton, {Wilson M.}",
year = "2017",
month = "7",
doi = "10.1136/tobaccocontrol-2016-052934",
volume = "26",
pages = "371--378",
journal = "Tobacco Control",
issn = "0964-4563",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Design and methods of the Population Assessment of Tobacco and Health (PATH) Study

AU - Hyland,Andrew

AU - Ambrose,Bridget K.

AU - Conway,Kevin P.

AU - Borek,Nicolette

AU - Lambert,Elizabeth

AU - Carusi,Charles

AU - Taylor,Kristie

AU - Crosse,Scott

AU - Fong,Geoffrey T.

AU - Michael Cummings,K.

AU - Abrams,David

AU - Pierce,John P.

AU - Sargent,James

AU - Messer,Karen

AU - Bansal-Travers,Maansi

AU - Niaura,Ray

AU - Vallone,Donna

AU - Hammond,David

AU - Hilmi,Nahla

AU - Kwan,Jonathan

AU - Piesse,Andrea

AU - Kalton,Graham

AU - Lohr,Sharon

AU - Pharris-Ciurej,Nick

AU - Castleman,Victoria

AU - Green,Victoria R.

AU - Tessman,Greta

AU - Kaufman,Annette

AU - Lawrence,Charles

AU - Van Bemmel,Dana M.

AU - Kimmel,Heather L.

AU - Blount,Ben

AU - Yang,Ling

AU - O’Brien,Barbara

AU - Tworek,Cindy

AU - Alberding,Derek

AU - Hull,Lynn C.

AU - Cheng,Yu Ching

AU - Maklan,David

AU - Backinger,Cathy L.

AU - Compton,Wilson M.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study’s design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA’s regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation’s burden of tobacco-related death and disease.

AB - Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study’s design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA’s regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation’s burden of tobacco-related death and disease.

UR - http://www.scopus.com/inward/record.url?scp=85021840121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021840121&partnerID=8YFLogxK

U2 - 10.1136/tobaccocontrol-2016-052934

DO - 10.1136/tobaccocontrol-2016-052934

M3 - Article

VL - 26

SP - 371

EP - 378

JO - Tobacco Control

T2 - Tobacco Control

JF - Tobacco Control

SN - 0964-4563

IS - 4

ER -